Solanezumab, an experimental Eli Lilly medication for Alzheimer's disease, slowed the rate of cognitive decline and memory loss by approximately 30% among patients in early stages of the disease. Eli Lilly says the results of its latest clinical trial provides initial evidence that solanezumab may have an impact on the course of the disease. Solanezumab is a monoclonal antibody, which Eli Lilly describes as a neuroprotector. Monoclonal antibodies are immune cells which are all clones of a unique parent cell...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment